Core Viewpoint - Chewy's stock has experienced a significant decline of approximately 78% since its peak in 2021, but there are indications that it may be on track for a reversal over the next five years [1]. Financial Performance - Chewy's financial performance has not aligned with its stock price trends; despite the stock's decline, the company has continued to grow its sales and turned profitable in 2022 [3][5]. - The company's autoship plan, which constitutes over 83% of its net sales, has been a key driver of its competitive advantage [4]. Market Position - Chewy's price-to-sales (P/S) ratio has decreased to 0.9, enhancing its value proposition compared to its previous P/S ratio of 7, which was significantly higher than Amazon's [4][8]. - The company has expanded its offerings to include a pet pharmacy, telehealth services, and in-person vet care, which positions it well for future growth [7][8]. Growth Projections - Analysts project a profit growth of 26% for this year and 24% for 2027, suggesting that as investors recognize this growth potential and Chewy's low valuation, stock purchases may increase [9]. Investment Outlook - Chewy's stock is viewed as potentially setting up for a dramatic rebound due to its low valuation and strong annual profit growth, which is expected to remain in double digits [11].

Core Insights - Digital healthcare is evolving with distinct approaches represented by Hims & Hers Health, Inc. (HIMS) focusing on consumer-first platforms and Doximity, Inc. (DOCS) targeting physician-centric solutions [1][2][3] Group 1: Company Models - HIMS operates a consumer-first digital health platform that connects individuals to licensed healthcare providers, enabling telehealth consultations and personalized treatments [1][3] - DOCS serves healthcare professionals by providing networking, clinical workflow tools, and targeted solutions for the healthcare industry [2][3] Group 2: Stock Performance & Valuation - Over the past three months, HIMS stock has decreased by 37.3%, while DOCS has declined by 44.7%. In the past year, HIMS lost 35.5% compared to DOCS's 60.7% decline [4] - HIMS has a forward price-to-sales (P/S) ratio of 1.7X, below its five-year median of 2.6X, while DOCS has a forward P/S ratio of 6.5X, below its five-year median of 13.6X [6] Group 3: Growth Drivers for HIMS - HIMS benefits from a scaling consumer-first digital health platform that integrates telehealth and prescriptions, supporting steady subscriber growth and recurring revenues [8][9] - The company is expanding into broader care categories, including hormone therapies and diagnostics, positioning itself closer to a proactive healthcare model [9][10] - Strategic partnerships and international expansion are enhancing HIMS's market reach and reinforcing its position as a leading digital health provider [10] Group 4: Growth Drivers for DOCS - DOCS's strong positioning is supported by a large physician network that drives engagement and enhances its value proposition [11] - The multi-product monetization model allows DOCS to deliver targeted digital engagement and diversify revenue streams [12] - Continued innovation in AI-powered tools is strengthening user engagement and long-term growth potential for DOCS [13] Group 5: Earnings Projections - The Zacks Consensus Estimate for HIMS's 2026 earnings per share (EPS) suggests a 5.7% decline from 2025 [16] - The Zacks Consensus Estimate for DOCS's fiscal 2026 EPS implies an improvement of 8.5% from fiscal 2025 [18] Group 6: Price Targets - The average price target for HIMS is $25.62, implying a 20.1% increase from the last close [21] - The average price target for DOCS is $39.55, implying a 62.5% increase from the last close [22] Group 7: Investment Outlook - Both companies carry a Zacks Rank 3 (Hold), but HIMS may offer better upside potential at current levels due to its consumer-focused expansion strategy [23][29] - Doximity commands a premium valuation supported by strong profitability and integration within physician workflows, but this may limit upside potential [28]

Company Performance - Teladoc (TDOC) closed at $5.42, reflecting a -3.39% change from the previous day, underperforming compared to the S&P 500's daily loss of 1.36% [1] - Over the past month, Teladoc's shares increased by 23.03%, outperforming the Medical sector, which saw a loss of 5.66%, and the S&P 500, which lost 1.76% [1] Upcoming Earnings - The upcoming earnings disclosure is anticipated to show an EPS of -$0.3, representing a 57.89% decline compared to the same quarter last year [2] - The consensus estimate for quarterly revenue is projected at $612.3 million, down 2.71% from the previous year [2] Full Year Projections - For the full year, earnings are projected at -$0.86 per share and revenue at $2.51 billion, indicating changes of +24.56% and -0.81% respectively from the previous year [3] - Recent changes to analyst estimates for Teladoc reflect short-term business trends, with positive revisions indicating analyst optimism about the company's profitability [3] Analyst Ratings and Industry Rank - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has shown a strong track record, with 1 rated stocks averaging an annual return of +25% since 1988 [5] - Teladoc currently holds a Zacks Rank of 3 (Hold), with the consensus EPS estimate having increased by 3.93% over the past month [5] - The Medical Services industry, part of the Medical sector, has a Zacks Industry Rank of 86, placing it in the top 36% of over 250 industries [6]

Core Insights - Teladoc's stock closed at $5.47, down 1.8%, underperforming the S&P 500 which lost 0.08% [1] - Over the past month, Teladoc's shares gained 14.85%, outperforming the Medical sector's loss of 2.21% and the S&P 500's loss of 2.16% [1] Earnings Performance - The upcoming EPS for Teladoc is projected at -$0.3, reflecting a 57.89% decline compared to the same quarter last year [2] - Revenue is estimated at $614.34 million, indicating a 2.39% decrease from the same quarter of the previous year [2] Fiscal Year Estimates - For the entire fiscal year, earnings are expected to be -$0.89 per share, with revenue projected at $2.52 billion, showing changes of +21.93% and -0.45% respectively from the previous year [3] - Recent analyst estimate revisions are crucial as they reflect near-term business trends, with positive revisions indicating a favorable business outlook [3] Zacks Rank and Performance - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has shown that 1 ranked stocks have an average annual return of +25% since 1988 [5] - Teladoc currently holds a Zacks Rank of 3 (Hold), with a recent 5.31% increase in the consensus EPS estimate over the last 30 days [5] Industry Insights - The Medical Services industry, part of the Medical sector, has a Zacks Industry Rank of 87, placing it in the top 36% of over 250 industries [6] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]

Group 1 - Teladoc shares increased by 5.1% to $5.57, with a notable trading volume, following a Deutsche Bank upgrade from Hold to Buy due to low valuation and plans to revamp the BetterHelp segment [1] - The stock has gained 6.4% over the past four weeks, indicating positive momentum [1] - The upcoming quarterly report is expected to show a loss of $0.31 per share, a year-over-year decline of 63.2%, with revenues projected at $614.34 million, down 2.4% from the previous year [2] Group 2 - The consensus EPS estimate for Teladoc has been revised 18% lower in the last 30 days, suggesting a negative trend in earnings estimate revisions, which typically does not lead to price appreciation [3] - Teladoc currently holds a Zacks Rank of 3 (Hold), indicating a neutral outlook [4] - In the same medical services industry, Bausch + Lomb has seen a significant EPS estimate increase of 43.5% over the past month, with a current Zacks Rank of 3 (Hold) [5]

Core Viewpoint - Teladoc Health Inc. reported stronger-than-expected quarterly results, with a notable increase in sales despite a projected loss for the upcoming quarters [2][3]. Financial Performance - In the latest quarterly report, Teladoc Health posted a loss of 14 cents per share, which was better than the consensus loss of 18 cents [2]. - Sales reached $642.27 million, exceeding the expected $635.24 million, driven by a 24% increase in other revenue streams, although access fees revenue declined by 4% [2]. - For Q1 2026, Teladoc expects a loss between 35-45 cents per share and sales of $598-$620 million, compared to the consensus loss of 25 cents and sales of $633.75 million [3]. - The fiscal 2026 outlook includes a projected loss of 70 cents to $1.10 per share and sales between $2.47 billion to $2.59 billion, against the consensus of 76 cents and $2.55 billion [3]. Analyst Reactions - Deutsche Bank upgraded Teladoc from Hold to Buy, citing compelling valuation and potential exit scenarios, with a price forecast of $11 [4]. - BTIG remains cautious, maintaining a Neutral rating, highlighting concerns over the macro environment and market saturation [4]. - Oppenheimer reiterated an Outperform rating but lowered the price target from $12 to $7, while Citigroup maintained a Neutral rating with a reduced target from $9 to $6 [5]. - Other analysts, including Piper Sandler and BMO Capital, also adjusted their price targets downward while maintaining their respective ratings [5][6]. Stock Performance - Teladoc shares are currently trading 21.8% above their 20-day simple moving average (SMA) but 12.5% below their 100-day SMA, indicating short-term strength amidst long-term struggles [7]. - Over the past year, shares have decreased by 40.65% and are closer to their 52-week lows than highs [7]. - The Relative Strength Index (RSI) is at 52.22, indicating neutral territory, while the MACD shows bullish momentum at -0.1341, above its signal line [8][9]. Price Action - As of the latest publication, Teladoc shares were up 5.57% at $5.59 [10]. - Key resistance level is identified at $6.50, with key support at $5.00 [10].

Group 1 - Zeta Global reported Q4 revenue growth of 25% year-over-year, reaching nearly $400 million, and beat EPS estimates with $0.28 compared to expectations of $0.24 [1] - The company is expected to achieve GAAP profitability this year and is currently trading at 16 times forward earnings, indicating an attractive valuation [1] - Zeta Global has a PEG ratio under 1.0 and an expected compounded annual growth rate of over 25% due to AI adoption, positioning it as a strong growth stock [1] Group 2 - Talkspace experienced a revenue surge of nearly 30% in Q4, reaching $63 million, and achieved a net income of $5 million, indicating a shift to profitability [1] - The company has seen significant growth in payor sessions and active members, reflecting its operational efficiency and improving margins [1] - Talkspace is considered a small-cap stock with substantial upside potential, making it a candidate for speculative investment [1]

Core Insights - Teladoc Health shares increased following the latest earnings report, indicating company-specific factors driving the stock's performance despite a mixed broader market [1][5] Performance Highlights - The company reported a quarterly loss of 14 cents per share, better than the consensus loss of 18 cents [2] - Sales rose to $642.27 million, surpassing the consensus estimate of $635.24 million [2] - Access fees revenue decreased by 4% to $521.6 million, while other revenue increased by 24% to $120.7 million [2] Revenue Breakdown - U.S. revenue fell 3% to $517.3 million, while international revenue grew by 19% to $125.0 million [3] - Integrated Care segment revenue increased by 5% to $409.1 million, while BetterHelp segment revenue declined by 7% to $233.2 million [3] - Adjusted EBITDA rose by 12% to $83.8 million [3] Future Guidance - For Q1 2026, the company expects a loss between 35-45 cents, with sales projected at $598-$620 million, compared to the consensus of 25 cents loss and $633.75 million in sales [4] - Fiscal 2026 guidance includes a loss of 70 cents to $1.10 and sales of $2.47 billion to $2.59 billion, against the consensus of 76 cents loss and $2.55 billion in sales [4] Technical Analysis - The stock is trading 5.2% below its 20-day simple moving average and 12.4% below its 100-day simple moving average, indicating short-term weakness [6] - Over the past 12 months, shares have significantly decreased and are closer to their 52-week lows [6] Momentum Indicators - The RSI is at 50.00, indicating neutral territory, while the MACD is at -0.05, suggesting bearish pressure [7] - The combination of neutral RSI and bearish MACD indicates mixed momentum [7] Analyst Consensus - The stock carries a Hold rating with an average price target of $9.26 [8] - Recent analyst actions include lowering targets by Evercore ISI Group to $5.00, Wells Fargo to $6.00, and Stifel to $6.00 [8] Price Action - Teladoc Health shares were up 13.44% at $5.28 at the time of publication [9]

Core Insights - The telehealth platform reported a quarterly profit of $20.6 million, which represents a decrease from $26 million in the same quarter of the previous year [1] Financial Performance - Quarterly profit: $20.6 million, down from $26 million year-over-year [1]

Group 1 - Medicare is ending broad coverage for telehealth services starting January 31, with exceptions primarily for rural areas and medical facility visits [1] - Teladoc Health experienced significant growth during the early pandemic as it provided essential telehealth services, leading to increased revenue and stock price [3] - The acquisition of Livongo aimed to enhance Teladoc's offerings but was made at high valuations, and the reopening of medical offices introduced competition from traditional healthcare providers and new entrants like Amazon [4] Group 2 - Teladoc's revenue has declined, and the company has struggled to achieve profitability, resulting in a stock price drop of over 70% in the past three years [5] - Despite the changes in Medicare coverage, Teladoc's revenue is primarily derived from commercial customers, particularly large enterprises and health plans, which may mitigate the impact of the Medicare shift on its growth [6]